Cepheid
CPHD
NASDAQ52.95
USD
- -
- -
Cepheid
CPHD
(NASDAQ)
Recent
price
52.95
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Cepheid (NYSE: CPHD) develops, manufactures, and markets molecular diagnostic systems and consumables for point-of-care and clinical laboratory testing. The company offers the GeneXpert platform, a cartridge-based system providing automated nucleic acid amplification testing for infectious diseases, oncology, and genetic disorders; Xpert MTB/RIF and Xpert XDR assays for tuberculosis detection; Xpert Xpress tests for respiratory pathogens, including SARS-CoV-2, influenza, and RSV; and over 30 FDA-cleared cartridges spanning categories such as women's health (e.g., CT/NG, BV), sexual health, and bloodstream infections. Cepheid's portfolio also includes the Omni platform for high-volume lab testing and services encompassing system installation, maintenance, training, and technical support. Founded in 1996 and headquartered in Sunnyvale, California, the company operates globally across North America, Europe, Asia-Pacific, Latin America, and the Middle East, serving hospitals, clinics, public health organizations, and reference laboratories. A subsidiary of Danaher Corporation since its $3.65 billion acquisition in 2016, Cepheid continues to innovate in decentralized diagnostics. Recent developments include the November 2024 launch of the Xpert CARBA-R assay for rapid detection of carbapenem-resistant organisms, enhancing antimicrobial stewardship; expansion of the Xpress portfolio with Xpert Xpress CoV-2/Flu/RSV near-patient tests amid ongoing respiratory surveillance needs; and strategic partnerships, such as deepened collaboration with the World Health Organization for tuberculosis programs in low-resource settings. In 2025, Cepheid announced manufacturing scale-up in response to global demand for next-generation GeneXpert GX VII systems and integrated AI-driven analytics for test result interpretation, reflecting its focus on operational efficiency and market expansion in emerging economies.